OptiNose (OPTN) to Release Earnings on Thursday

OptiNose (NASDAQ:OPTN) will release its earnings data before the market opens on Thursday, August 8th. Analysts expect OptiNose to post earnings of ($0.08) per share for the quarter. OptiNose has set its FY 2024 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.

OptiNose (NASDAQ:OPTN) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The company had revenue of $14.88 million for the quarter, compared to analysts’ expectations of $13.95 million. On average, analysts expect OptiNose to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptiNose Price Performance

OPTN traded up $0.05 during midday trading on Tuesday, hitting $1.04. 379,971 shares of the company’s stock traded hands, compared to its average volume of 851,868. The company has a market cap of $117.00 million, a PE ratio of -3.61 and a beta of -0.12. The stock’s fifty day simple moving average is $1.10 and its 200-day simple moving average is $1.26. OptiNose has a one year low of $0.80 and a one year high of $2.10.

Wall Street Analyst Weigh In

OPTN has been the topic of several recent research reports. Lake Street Capital cut their price objective on shares of OptiNose from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Wednesday, May 15th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of OptiNose in a report on Wednesday, May 15th.

Insider Buying and Selling at OptiNose

In other OptiNose news, CEO Ramy A. Mahmoud sold 111,426 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $127,025.64. Following the transaction, the chief executive officer now owns 1,206,978 shares in the company, valued at $1,375,954.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other OptiNose news, CEO Ramy A. Mahmoud sold 111,426 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $127,025.64. Following the transaction, the chief executive officer now owns 1,206,978 shares in the company, valued at $1,375,954.92. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael F. Marino III sold 49,408 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $1.14, for a total transaction of $56,325.12. Following the completion of the sale, the insider now owns 550,464 shares in the company, valued at approximately $627,528.96. The disclosure for this sale can be found here. Insiders have sold a total of 189,933 shares of company stock worth $217,636 over the last 90 days. Insiders own 2.70% of the company’s stock.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.